Clinical trial
EXTENT: EXtended Tolerability and Efficacy of a Novel Formulation of…
NCT00391534 · Desitin Arzneimittel GmbH, Industry · Terminated
Key facts
| NCT number | NCT00391534 |
|---|---|
| Title | EXTENT: EXtended Tolerability and Efficacy of a Novel Formulation of Oxcarbazepine in a Trial in Partial Epilepsy |
| Official title | Safety and Efficacy of a Novel Modified Release Formulation of Oxcarbazepine (OXC MR) vs an Immediate Release Oxcarbazepine (OXC IR) Product in Patients With Partial Epilepsy |
| Lead sponsor | Desitin Arzneimittel GmbH, Industry |
| Collaborators | FGK Clinical Research GmbH Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Partial Epilepsy |
| Intervention type | Drug |
| Interventions | modified release formulation of oxcarbazepine (OXC MR), immediate release formulation of oxcarbazepine (OXC IR) |
| Enrollment | 100 |
| Start date | Oct 1, 2006 |
| Primary completion | Nov 1, 2009 |
| Completion | Nov 1, 2009 |
| First posted | Oct 24, 2006 |
| Last update posted | Apr 15, 2010 |
| Countries | Germany |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: